K-1728

K-1728 is an investigational, oral, pan-mutant selective phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor developed by KymaThera. It is designed to selectively target both kinase domain and helical domain mutations of PI3Kα (encoded by the PIK3CA gene) while sparing wild-type PI3Kα, thereby minimizing wild-type-mediated toxicities such as hyperglycemia. K-1728 is being evaluated in Phase 1/2 clinical trials as a monotherapy and in combination regimens (such as with endocrine therapy and a CDK4/6 inhibitor) for the treatment of advanced or metastatic solid tumors, particularly HR-positive, HER2-negative breast cancer harboring PIK3CA mutations. It is also being explored as a monotherapy for PI3Kα-driven vascular malformations.